Literature DB >> 33483790

Supported progressive resistance exercise training to counter the adverse side effects of robot-assisted radical prostatectomy: a randomised controlled trial.

Ruth E Ashton1, Jonathan J Aning2, Garry A Tew3, Wendy A Robson4, John M Saxton5.   

Abstract

PURPOSE: To investigate the effects of a supported home-based progressive resistance exercise training (RET) programme on indices of cardiovascular health, muscular strength and health-related quality of life (HR-QoL) in prostate cancer (PCa) patients after treatment with robot-assisted radical prostatectomy (RARP).
METHODS: This study was a single-site, two-arm randomised controlled trial, with 40 participants randomised to either the intervention or control group over a 10-month period. In addition to receiving usual care, the intervention group completed three weekly RET sessions using resistance bands for 6 months. Participants performed 3 sets of 12-15 repetitions for each exercise, targeting each major muscle group. The control group received usual care only. Brachial artery flow-mediated dilatation (FMD) was the primary outcome and assessed at baseline, 3 and 6 months. Secondary outcomes included body weight, body fat, aerobic fitness, strength and blood-borne biomarkers associated with cardiometabolic risk.
RESULTS: There was no significant difference between the groups in FMD at 3 or 6 months. However, there were improvements in aerobic exercise capacity (P < 0.01) and upper- (P < 0.01) and lower-limb (P = 0.01) strength in favour of the RET group at 6 months, accompanied by greater weight loss (P = 0.04) and a reduction in body fat (P = 0.02). Improvements in HRQoL were evident in the RET group at 3 and 6 months via the PCa-specific component of the FACT-P questionnaire (both P < 0.01). Five adverse events and one serious adverse event were reported throughout the trial duration.
CONCLUSION: This study demonstrates that home-based RET is an effective and safe mode of exercise that elicits beneficial effects on aerobic exercise capacity, muscular strength and HR-QoL in men who have undergone RARP. TRIAL REGISTRATION: ISRCTN10490647.

Entities:  

Keywords:  Cardiometabolic; Prostate cancer; Resistance exercise; Robot-assisted radical prostatectomy

Mesh:

Year:  2021        PMID: 33483790      PMCID: PMC7822752          DOI: 10.1007/s00520-021-06002-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  34 in total

1.  Concurrent validation of the OMNI-resistance exercise scale of perceived exertion with Thera-band resistance bands.

Authors:  Juan C Colado; Xavier Garcia-Masso; Travis N Triplett; Jorge Flandez; Sebastien Borreani; Victor Tella
Journal:  J Strength Cond Res       Date:  2012-11       Impact factor: 3.775

2.  Allometric scaling of diameter change in the original flow-mediated dilation protocol.

Authors:  Greg Atkinson; Alan M Batterham
Journal:  Atherosclerosis       Date:  2012-12-08       Impact factor: 5.162

3.  Metabolic adaptations in skeletal muscle, adipose tissue, and whole-body oxidative capacity in response to resistance training.

Authors:  Malin Alvehus; Niklas Boman; Karin Söderlund; Michael B Svensson; Jonas Burén
Journal:  Eur J Appl Physiol       Date:  2014-04-08       Impact factor: 3.078

4.  The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer.

Authors:  Laurien M Buffart; Robert U Newton; Mai J Chinapaw; Dennis R Taaffe; Nigel A Spry; James W Denham; David J Joseph; David S Lamb; Johannes Brug; Daniel A Galvão
Journal:  Cancer       Date:  2015-04-17       Impact factor: 6.860

5.  The Godin-Shephard leisure-time physical activity questionnaire: validity evidence supporting its use for classifying healthy adults into active and insufficiently active categories.

Authors:  Steve Amireault; Gaston Godin
Journal:  Percept Mot Skills       Date:  2015-03-23

6.  Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).

Authors:  Lena Ansmann; Nicola Winter; Nicole Ernstmann; Axel Heidenreich; Lothar Weissbach; Jan Herden
Journal:  BJU Int       Date:  2018-04-20       Impact factor: 5.588

7.  Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable.

Authors:  Kristin L Campbell; Kerri M Winters-Stone; Joachim Wiskemann; Anne M May; Anna L Schwartz; Kerry S Courneya; David S Zucker; Charles E Matthews; Jennifer A Ligibel; Lynn H Gerber; G Stephen Morris; Alpa V Patel; Trisha F Hue; Frank M Perna; Kathryn H Schmitz
Journal:  Med Sci Sports Exerc       Date:  2019-11       Impact factor: 5.411

8.  Effects of short-term, medium-term and long-term resistance exercise training on cardiometabolic health outcomes in adults: systematic review with meta-analysis.

Authors:  Ruth E Ashton; Garry A Tew; Jonathan J Aning; Stephen E Gilbert; Liane Lewis; John M Saxton
Journal:  Br J Sports Med       Date:  2018-06-22       Impact factor: 13.800

9.  Cross-sectional study of patient-reported fatigue, physical activity and cardiovascular status in men after robotic-assisted radical prostatectomy.

Authors:  Ruth E Ashton; Garry A Tew; Wendy A Robson; John M Saxton; Jonathan J Aning
Journal:  Support Care Cancer       Date:  2019-04-10       Impact factor: 3.603

Review 10.  Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Liam Bourke; Dianna Smith; Liz Steed; Richard Hooper; Anouska Carter; James Catto; Peter C Albertsen; Bertrand Tombal; Heather A Payne; Derek J Rosario
Journal:  Eur Urol       Date:  2015-11-26       Impact factor: 20.096

View more
  1 in total

Review 1.  Exercise medicine for cancer cachexia: targeted exercise to counteract mechanisms and treatment side effects.

Authors:  Georgios Mavropalias; Marc Sim; Dennis R Taaffe; Daniel A Galvão; Nigel Spry; William J Kraemer; Keijo Häkkinen; Robert U Newton
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-27       Impact factor: 4.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.